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Summary
 
We used a new monoclonal antibody (mAb 130) to analyze the intracellular trafficking and
surface expression of H2-M3, the major histocompatibility complex class Ib molecule that pre-
sents 
 
N
 
-formylated peptides to cytotoxic T cells. M3 surface expression is undetectable in most
cell types due to the paucity of endogenous antigen. M3 is induced on the cell surface by addi-
 
tion of high-affinity 
 
N
 
-formylated peptides from mitochondria and listeria. Peptide-induced M3
expression is most efficient on antigen presenting cells. Basal and inducible expression of M3 is
transporter associated with antigen processing (TAP)-dependent, distinguishing M3 from the
class Ib molecules TL and CD1. Unlike the expression of class Ia molecules and a previously
described M3/L
 
d
 
 chimera, surface expression of M3 cannot be rescued by lowered tempera-
ture, suggesting that the 
 
a
 
3 domain and transmembrane region of M3 may control trafficking.
Pulse–chase analysis and use of trafficking inhibitors revealed a pool of empty M3 in the endo-
plasmic reticulum or early Golgi apparatus. Addition of exogenous peptide allows maturation
with kinetics matching those of D
 
d
 
. The lack of endogenous 
 
N
 
-formylated peptide allows dis-
covery of novel pathogen-derived peptides in normal antigen presenting cells. The nonpoly-
morphic nature of M3 and its ability to present bacterial antigens rapidly and dominantly make
it an attractive target for peptide vaccination strategies.
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N
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T
 
he H2-M3 MHC class Ib molecule differs from class Ia
molecules in expression patterns, levels, and polymor-
phism (1, 2). H2-M3 was first identified as a component of
a minor histocompatibility antigen, maternally transmit-
ted antigen (Mta; 3, 4).
 
1
 
 Mta was found to consist of an
 
N
 
-formylated mitochondrial peptide (maternally transmit-
ted factor [MTF]) from NADH dehydrogenase subunit
I(ND1) bound to M3 (5). Further studies have shown that
the binding specificity of M3 is for 
 
N
 
-formylated peptides
with hydrophobic residues (6, 7), whereas the affinity of
M3 for nonformylated peptides is 100–1,000-fold lower
(8). As the class Ia molecules K and D do not bind 
 
N
 
-for-
mylated peptides appreciably (9), the binding specificity of
M3 for 
 
N
 
-formylated peptides may have been selected in
evolution for the specialized presentation of a conserved
structure of bacterial peptides. Because only mitochondria
and prokaryotes initiate protein synthesis with 
 
N
 
-formyl-
ated methionine, CTLs specific for 
 
N
 
-formylated bacterial
peptides would have little risk of cross-reacting to self-pep-
tides. Protection afforded by adoptive transfer of M3-
restricted CTLs specific for 
 
Listeria monocytogenes
 
 peptide
LemA (fMIGWII) has shown the importance of M3 in the
host defense against intracellular pathogens (10–13). Addi-
tional listerial antigens presented by M3 have also been
identified, such as FR38 (fMIVIL; 14) and fMIVTLF (15).
The 
 
H2-M3
 
 gene is located in the telomeric end of the
mouse 
 
H-2
 
 complex and shares many conserved features
with class Ia MHC molecules (4, 16). By Northern blot
analysis, it has been shown to be expressed in most tissues
of all strains of mice at about one-twentieth of the level of
class Ia molecules (4). 
 
H2-M3
 
 message can be detected by
RT-PCR as early as day eight in embryonic development,
and surface expression (17) has been detected by CTL assay
in a thymic epithelial cell (TEC) line, which suggests that
it may be active in shaping the TCR repertoire (Wang,
C.-R., unpublished data). The crystal structure of M3 with
bound ND1 reveals that the 
 
N
 
-formylated peptide is shifted
 
1
 
Abbreviations used in this paper:
 
 
 
b
 
2m, 
 
b
 
2-microglobulin; ER, endoplasmic
reticulum; LCMV, lymphocytic choriomeningitis virus; Mta, maternally
transmitted antigen; MTF, maternally transmitted factor; TAP, trans-
porter associated with antigen processing; TEC, thymic epithelial cell.  
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one residue along the groove relative to peptides in other
class I structures (18), and the optimal length of M3-bind-
ing peptide would be a heptamer. Additionally, the residues
surrounding the M3 antigen binding groove are predomi-
nately hydrophobic, which may explain why most M3-bound
peptides to date are hydrophobic.
Because of the unusual antigens presented by M3, it is of
interest to see if M3 peptide loading and antigen processing
follows the pathway outlined for class Ia molecules or
whether it displays some nonclassical behaviors as reported
for other class Ib molecules, i.e., TL and CD1 (19, 20). MHC
class I molecules generally derive antigens from intracellular
sources. The pathway involves cytosolic degradation of
polypeptides by the proteasome complex (21) and transport
to the endoplasmic reticulum (ER) lumen by the transporter
associated with antigen processing (TAP) (22, 23). Nascent
MHC class Ia molecules dimerize with 
 
b
 
2-microglobulin
(
 
b
 
2m) with the aid of the chaperone calnexin (24–26).
Subsequently, a complex involving a second chaperone,
calreticulin, and tapasin is formed (27). Tapasin may aid in
both the final folding of MHC class I molecules and form-
ing the peptide loading complex with TAP (28). Upon sta-
ble formation of the ternary complex of MHC class I heavy
chain, 
 
b
 
2m, and peptide (usually a nonamer), the molecule
is transported through the Golgi apparatus to the cell surface.
Variations in the pathway have been outlined in mutant
cell lines, particularly those deficient in TAP (29), calnexin
(30, 31), 
 
b
 
2m (32), and tapasin (28, 33, 34). Although sur-
face expression of high levels of MHC class Ia molecules is
peptide dependent, analysis at reduced temperature has
shown that it is possible for an empty heavy chain–
 
b
 
2m
dimer to reach the cell surface and be stabilized by the ad-
dition of peptide; however, this is not the major route of
maturation in normal cells (35).
Due to the lack of an appropriate serological reagent, the
antigen presenting pathway and surface expression of M3
have not been visualized for the native molecule. Attempts
to produce anti-M3 alloantibodies have failed (1), most likely
because of the minimal divergence between different M3
alleles (2) and low level of M3 expression as predicted from
its transcript levels. In this study, we have developed a
hamster mAb against purified recombinant M3 that allows
us to detect M3 expression directly and compare its behav-
ior with that of class Ia molecules. Similar to class Ia, M3
expression is TAP-dependent; however, M3 differs from
class Ia molecules in several respects. M3 behaves in a nor-
mal cell as class Ia molecules behave in a TAP-deficient
background. This results in virtually undetectable expres-
sion of M3 on all cell types except B cells. M3 does not
move to the cell surface without peptide at reduced tem-
peratures as do classical class I molecules (35). The majority
of M3 is retained in an immature peptide-receptive state
and traffics rapidly to the cell surface upon addition of ex-
ogenous peptide. This resulting increase in M3 on the cell
surface shows long-term stability. This property, combined
with the lack of competition from self-antigens, assures po-
tent display of even small amounts of bacterial peptide. The
ability to analyze M3 surface expression allows determina-
 
tion of the binding specificity of M3 and may prove useful
in predicting antigenic peptides.
 
Materials and Methods
 
Cell Lines and Reagents.
 
The following mAbs were purchased
from PharMingen: FITC–anti-CD3 (2C11), FITC–anti–TCR-
 
b
 
(H57-597), FITC–anti-K
 
b
 
 (AF6-88.5), mouse anti–hamster IgG–
FITC, PE–anti-B220, and PE–anti-CD11c (HL3). PE–F4/80, an
antibody specific to macrophage, was purchased from Caltag Labs.
Synthetic peptides were purchased from Research Genetics. All
peptides were 
 
.
 
90% pure as determined by mass spectrometry.
Peptides were dissolved in DMSO at concentrations of 1–2 mg/ml.
B cell lines A20 and SP2/0, macrophage cell lines P388 and J774,
and thymoma BW5147 cells were purchased from American
Type Culture Collection. RMA and RMA-S cells were provided
by Dr. John Monaco (University of Cincinnati, Cincinnati, OH).
TECs and thymic nurse cells (TNC.R3.1) were provided by Dr.
Jim Miller (University of Chicago). Chemotactic peptide (fMLFF),
normal hamster sera, human 
 
b
 
2m, brefeldin A, phenylarsine oxide,
chloroquine, cytochalasin B, and cycloheximide were purchased
from Sigma Chemical Co. 
 
Immunization and Production of H2-M3–specific Antibodies.
 
Solu-
ble M3 protein was purified from the culture supernatant of a
 
Drosophila melanogaster 
 
cell line (SC2) cotransfected with the trun-
cated 
 
M3
 
 and murine 
 
B2m
 
 cDNAs as described by Castaño et al.
(36). 100 
 
m
 
g of purified M3 was emulsified in complete Freund’s
adjuvant and injected subcutaneously into 8-wk-old Armenian
hamsters. Two to three additional immunizations were adminis-
tered subcutaneously in incomplete Freund’s adjuvant at 2-wk
intervals. 4 d after the last immunization, lymphocytes isolated from
immunized hamster were used to produce hybridoma cell lines
by fusion with murine myeloma cell line SP2/0 using PEG1500.
Hybridoma supernatants were screened in ELISA plates coated
with 100 ng of purified M3. Positive wells were then tested for
the ability to block the recognition of M3-restricted CTLs.
 
T Cell Clones and Cytotoxicity Assays.
 
MTF
 
a
 
-specific, M3-
restricted CTLs (4E3, B6, and 5G5) (37, 38) were provided by
Dr. Kirsten Fischer Lindahl (UT Southwestern Medical Center,
Dallas, TX). P14, a lymphocytic choriomeningitis virus (LCMV)
peptide–specific D
 
b
 
-restricted CTL line, was provided by Dr.
Philip Ashton-Rickardt (University of Chicago). RMA cells (MTF
 
a
 
,
M3
 
wt
 
) and LCMV peptide-pulsed RMA-S cells were used as tar-
gets in a standard 
 
51
 
Cr-release assay for M3-restricted CTLs and
P14 CTLs, respectively. Target cells (10
 
6
 
 cells) were labeled with
100 
 
m
 
Ci [
 
51
 
Cr]sodium chromate for 1 h at 37
 
8
 
C. Target cells (10
 
4
 
cells) were added to round-bottom microtiter wells containing
effector cells. Supernatants containing anti-M3 or nonrelevant
antibody were added to the wells at a final dilution of 1:4. After 4 h
incubation at 37
 
8
 
C, 100 
 
m
 
l of supernatant from each well was as-
sayed for 
 
51
 
Cr release. Results are given as percentage of specific
lysis 
 
5 
 
(experimental 
 
2
 
 spontaneous release) 
 
3
 
 100/(maximal
release 
 
2
 
 spontaneous release).
 
Cell Preparations.
 
Single-cell suspensions from thymus, spleen,
Peyer’s patch, and lymph node were prepared by pressing the or-
gans between the frosted ends of two microscope slides. Perito-
neal macrophages were obtained by peritoneal lavage with
DMEM (GIBCO BRL). Red blood cells were removed when
necessary by hypotonic lysis. Intestinal epithelial cells were pre-
pared and purified through discontinuous 40/70% Percoll gradi-
ent centrifugation as described by Tagliabue et al. (39). LPS blasts
and ConA blasts were prepared by culturing splenocytes with
5 
 
m
 
g/ml of LPS and 3 
 
m
 
g/ml of ConA, respectively, in RPMI 
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1640 (GIBCO BRL) with 10% fetal bovine serum, 2 mM
 
l
 
-glutamine, 20 mM Hepes, 50 
 
m
 
M 2-ME, penicillin, and strep-
tomycin (RPMI 10 media) for 48 h at 37
 
8
 
C.
 
Flow Cytometric Analysis of M3 Upregulation.
 
10
 
6
 
 cells were
incubated in RPMI 10 media with or without peptides for 18–20 h
at 37 or 26
 
8
 
C. Cells were harvested and washed three times with
PBS before cell surface staining experiments. M3 staining was de-
tected by adding 100 
 
m
 
l hybridoma supernatants followed by
mouse anti–hamster IgG FITC. Staining with each reagent was
performed for 30 min on ice in immunofluorescence buffer
(HBSS containing 2% fetal bovine serum and 0.1% NaN
 
3
 
), fol-
lowed by washing with the same buffer. The stained cells were
analyzed by flow cytometry using a FACSCalibur™ with Cell-
quest™ software (Becton Dickinson). When inhibitors were
present, they were added 3 h before the addition of peptide and
remained during the overnight incubation with or without peptide
at 37
 
8
 
C.
 
Cell Labeling, Immunoprecipitation, and SDS-PAGE Analysis.
 
LPS
blasts from C57BL/6 mice were surface labeled by lactoperoxi-
dase-catalyzed iodination (40). Labeled cells were lysed in buffer
containing 50 mM Tris, pH 7.4, 150 mM NaCl, 0.5% NP-40, 20
mM iodoacetamide, 1 mM PMSF, and 10 mg/ml aprotinin. Radio-
labeled lysates were precleared successively with protein A–Seph-
arose (Pharmacia) and normal hamster sera bound to protein
A–Sepharose at 4
 
8
 
C for 4 h. 1 ml of various mAb supernatants
coupled to protein A–Sepharose were used for immunoprecipita-
tion with precleared cell lysate at 4
 
8
 
C overnight. Immune com-
plexes were washed with a buffer containing 0.25% NP-40, 5 mM
PMSF, 10 mM Tris, pH 8.0, 150 mM NaCl, 5 mM KI, and 5 mM
EDTA. After extensive washing, the immunoprecipitates were
eluted by boiling for 5 min in SDS sample buffer and analyzed on
12.5% polyacrylamide gel.
For pulse–chase experiments, 5 
 
3
 
 10
 
6
 
 P388 cells were used for
each time point. After starvation in 3 ml of methionine/cysteine–
free medium for 2 h, cells were pulsed with 0.5 mCi/ml of 
 
35
 
S
Translabel (ICN Biomedicals, Inc.) for 20 min and then chased in
complete medium for various periods of time in the presence or
absence of 10 
 
m
 
M of LemA peptide. Aliquots of cells for each
chase point were lysed in lysis buffer. The lysates were precleared
and M3 molecules were immunopurified as described. Immune
complexes were eluted from the protein A–Sepharose beads by
boiling with SDS-PAGE sample buffer containing 0.6% SDS and
1% 2-ME for 5 min. Eluates were diluted 1:5 with distilled water
and split into two equal aliquots, one of which received 2 mU of
endoglycosidase (EndoH) at pH 5.5, followed by overnight incu-
bation at 37
 
8
 
C. Samples were analyzed by 12.5% SDS-PAGE and
fluorography.
 
Results
 
Development of Monoclonal Reagents for the Detection of M3
Expression.
 
We generated mAbs against M3 by immu-
nization of hamsters with recombinant soluble M3 protein.
Recombinant M3 was purified from the culture superna-
tant of SC2 cells transfected with murine 
 
b
 
2m and truncated
M3 cDNAs. Three clones (mAb 32, 38, and 130) reacting
positively with purified M3 by ELISA were screened for
the ability to block the recognition of M3 by M3-restricted
CTLs. One of the clones, mAb 130, significantly blocked
the killing of all MTF-specific, M3-restricted CTL clones
tested but had no effect on H-2D
 
b
 
–restricted LCMV pep-
tide–specific killing by the P14 CTL line (Fig. 1). Western
blot analysis of purified recombinant protein showed that
mAb 130 reacts with the M3 heavy chain and not with the
 
b
 
2m light chain (data not shown).
 
M3 Surface Expression on a Range of Cell Types.
 
Flow cyto-
metric analysis was performed to detect M3 surface expres-
sion from various lymphoid organs. mAb 130 detected low
levels of M3 on cells from the spleen, Peyer’s patch, and
lymph node (Fig. 2), consistent with the finding that 
 
H2-M3
 
message is much less abundant than that of class Ia genes
(4). M3 is not detectable on the surfaces of thymocytes, al-
Figure 1. M3-restricted CTL killing is inhibited by mAb 130. Anti-
MTFa CTL clones 4E3, B6, and 5G5 were incubated with RMA cells
(M3wt, MTFa) in the presence of either 100 ml mAb 130 hybridoma su-
pernatant (solid bars) or 100 ml of RPMI 10 media (hatched bars) during
a Cr-release assay. Clone P14 recognizes an LCMV peptide in the con-
text of Db and is not affected by mAb 130. The E/T ratio was 9:1 for 4E3,
12:1 for B6, 4:1 for 5G5, and 10:1 for P14.
Figure 2. Low-level expression of M3 in lymphoid tissues. Single-cell
suspensions from C57BL/6 thymus, spleen, lymph node, and Peyer’s
patch were stained with mAb 130 followed by secondary detection by
FITC-conjugated mouse anti–hamster IgG. Dotted lines represent stain-
ing with a control hamster antibody; black lines are mAb 130 specific. 
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though M3 message is readily detectable in thymus RNA.
Expression of M3 on the cell surface was also found on
LPS blasts but not on cells activated by ConA (Table I).
Low or undetectable M3 surface staining was observed on
various cell types known to be targets for M3-specific
CTLs (Table I). Although 
 
H2-M3
 
 message can be upregu-
lated by IFN-
 
g
 
 (17), this treatment has no effect on M3
surface expression in cell lines (data not shown). Further-
more, an M3 transfectant (TR8.4a; reference 4) of a fibro-
blast cell line (B10.CAS2) that expresses high levels of 
 
H2-
M3
 
 mRNA does not show detectable surface expression.
The level of 
 
H2-M3
 
 message does not appear to correlate
with the level of M3 surface expression, suggesting that
surface expression of M3 may be controlled posttranscrip-
tionally.
 
Induction of M3 Surface Expression by Increased Peptide Supply.
 
Because the supply of endogenous 
 
N
 
-formylated peptides
is limited to 13 potential peptides from mitochondria, it re-
mained possible that peptide supply had an influence on
M3 surface expression. To examine whether increased
peptide supply can induce M3 surface expression, LPS blast
cells from C57BL/6 mice were incubated overnight with
10 
 
m
 
M of Fr38 peptide (fMIVIL), an antigenic peptide for
a listeria-specific, M3-restricted CTL. Surface iodination
was followed by immunoprecipitation with anti-M3 anti-
bodies. Both mAb 38 and mAb 130 immunoprecipitated
significant amounts of M3 heavy chain (41 kD) and 
 
b
 
2m
(12 kD) from Fr38-treated cells (Fig. 3). The amount of
surface iodinated M3 is substantially less in untreated cells.
In contrast, the amount of another class Ib molecule, CD1,
is not affected by the peptide treatment.
Enhanced surface expression of M3 by incubation with
Fr38 peptide was further confirmed by immunofluores-
cence assay. M3 surface expression in splenocytes is found
to increase approximately fivefold after incubation with 10
 
m
 
M of Fr38, whereas K
 
b
 
 expression is not affected (Fig. 4 A).
Two-color immunofluorescence staining was performed to
see whether the levels of M3 induction differ among cell
types in the spleen (Fig. 4 B). Whereas CD3
 
1
 
 T cells are
only induced twofold (as assessed by change in fluorescence
intensity), B cells are able to show a ninefold induction of
M3. Macrophage and dendritic cell populations both dis-
play M3 at three to four times the level of uninduced cells.
Unlike splenic T cells, thymocytes do not show significant
induction of M3. Peritoneal macrophages also induce M3
to fourfold above background levels (Table I). Addition-
ally, M3 induction can be detected on the following cell
lines: B cell A20, SP2/0, macrophage J774, P388, T cell line
RMA, TEC, and thymic nurse cell line TNC.R3.1. How-
ever, unlike other class Ib molecules (i.e., TL and CD1; ref-
erence 41–43), M3 expression and induction is not detected
on the surface of intestinal epithelial cells (Table I). It is
worth noting that peptide treatment has only a minimal ef-
fect on an M3-transfected fibroblast cell line, further sug-
gesting the upregulation of M3 surface expression by exog-
enous peptide is cell type specific.
 
Table I.
 
Reactivity of Anti-M3 mAb
 
Cell type Untreated Treated
Thymocyte
 
26
 
Splenocyte
 
1 111
 
LPS blast
 
1 111
 
ConA blast
 
21
 
Intestinal epithelial cell
 
22
 
Peritoneal macrophage
 
21 1
 
B cell line
A20
 
11 1
 
SP 2/0
 
21
Macrophage cell line
P388 21 1
J774 21
T cell line
BW5147 22
RMA 21
RMA-S 26
TEC 21
Thymic nurse cell line TNC.R3.1 21
Fibroblast cell line
L929 26
B10.CAS2 22
TR8.4a 26
Reactivity of anti-M3 antibody was determined on cells incubated over-
night with 10 mM of LemA (treated) or without peptide (untreated) by
flow cytometric analysis. The reactivity is indicated as follows: 2, nega-
tive staining; 6, ,50% reactivity above background; the number of
‘1’ (1, 11, 111) correlates with the staining intensity of cells.
Figure 3. mAb 130 and mAb 38 immunoprecipitate M3 on the cell
surface. LPS blasts from C57BL/6 spleen were incubated overnight with
or without 10 mM Fr38, surface labeled with 125I, lysed, and precipitated
with either M3-specific antibodies (mAb 130 and mAb 38) or a control
antibody to mouse CD1 (mAb 5C6). Eluted proteins were separated by
SDS-PAGE through a 12.5% gel.427 Chiu et al.
The Range of Antigens Presented by M3. Flow cytometric
analysis was used to test a panel of N-formylated peptides
for their ability to induce increased surface expression of
M3. Fig. 5 A shows the extent to which each peptide en-
hances M3 expression after overnight incubation with 10
mM peptide. Not all N-formylated peptides or even all mi-
tochondrially derived N-formylated peptides increase the
surface level of M3 significantly. The listerial peptides
LemA and Fr38 have the highest affinity for M3, followed
by ND1 and COI, the only two mitochondrial peptides
that cause significant induction. ND4 and COII enhance
M3 expression only slightly, and the remaining mitochon-
drial sequences show no detectable binding. A nonformy-
lated variant of ND1 cannot stabilize the surface expression
of M3, confirming the requirement of an N-formyl group
for high-affinity binding to M3. The relative efficiency of
M3 induction by each sequence was further compared by
titration of peptide concentration. Fig. 5 B shows the in-
duction of M3 with respect to peptide concentration for
high- (LemA, Fr38, ND1, COI) and low-affinity (COII,
ND4) peptides. Maximal binding was approached with 10–
20-mM concentrations with all tested peptides. Increased
peptide concentration for lower affinity peptides cannot in-
duce high levels of M3 on the surface. The relative ability
of peptides to induce surface M3 correlates with affinities
determined previously by competitive inhibition CTL as-
says (38). The peptides that bind to M3 with highest affin-
ity are also those against which immunized animals are able
to develop a CTL response, namely, ND1 (5, 38), COI
(44), LemA (12), and Fr38 (14). ND4 and COII induce
slight increases in M3 surface expression, although no CTL
clones have been developed against these peptides. The pep-
tides that bind to M3 show little common motif other than
the N-formylated methionine and some hydrophobic resi-
dues. However, the peptides that do not bind M3 frequently
contain charged residues at positions two and three. This is
compatible with the predictions based on the crystal struc-
ture of the M3–ND1 complex (18), in which the interacting
surface between ND1 and M3 is predominantly hydropho-
bic. The chemotactic peptide fMLFF also binds with high
affinity to M3 (Fig. 5 A), confirming results obtained by
competitive inhibition of Fr38-specific M3-restricted CTL
lysis (45). Although this chemotactic peptide is short in
length, its hydrophobicity allows significant binding to M3.
M3 Is Not Inducible at 278C. The response of M3 to
antigen supply is similar to that of class Ia molecules in the
absence of TAP. In TAP-deficient cells, class Ia expression
is increased at reduced temperature and can be stabilized by
the addition of peptide, suggesting that empty class I mole-
cules are transported to the cell surface but are not stable.
To examine whether surface expression of M3 can be in-
duced by lowered temperature, we compared M3 surface
expression on B6 splenocytes at 378C and 278C by FACS™
analysis. Fig. 6 A shows that surface expression of M3 can-
not be induced by incubation at low temperature, suggest-
ing that the empty M3 molecule is not efficiently trans-
ported to the cell surface. In contrast to class Ia, M3 induction
is at least 50% less efficient at 278C, even after overnight in-
cubation with peptide (Fig. 6 B). This reduction may be
due to the effect of temperature reduction on endocytosis
and intracellular transport, which could cause a reduction
in peptide delivery to the ER.
Figure 4. Cell type–specific induction of M3 on splenocytes. Spleno-
cytes from a C57BL/6 adult mouse were incubated overnight with or
without 10 mM Fr38 (fMIVIL). Cells were stained with mAb 130 fol-
lowed by FITC-conjugated anti–hamster IgG and double staining with
PE-conjugated markers for T cells (CD3), B cells (B220), macrophages
(F4/80), or dendritic cells (HL3). (A) Histograms represent fluorescence
profile from total splenocytes. Dotted lines, background staining with iso-
type control antibodies; thin black lines, mAb 130 or Y3 (anti–H-2Kb)
staining of untreated cells; bold black lines, mAb 130 or Y3 staining of
peptide-treated cells. (B) Histograms represent populations gated for ex-
pression of the indicated markers. Unfilled peaks, background staining
with an isotype control hamster antibody specific for TNP; filled peaks,
mAb 130-specific staining.428 H2-M3 Trafficking Is Affected by Antigen Supply
Effect of Antigen Trafficking Inhibitors and TAP on M3 In-
duction. To determine whether the induction of M3 sur-
face expression by peptide requires new protein synthesis,
transport from ER, or acidification of the endosomal com-
partment, we analyzed the effects of various inhibitors on
M3 induction by peptide (Fig. 7). M3 surface expression is
not significantly affected by the protein translation inhibitor
cycloheximide, suggesting that there is an existing intracel-
lular pool of M3 that remains available for binding in-
creased antigen supply. Expression is not increased in the
presence of exogenous human b2m, which suggests that
there is little trafficking of free M3 heavy chain to the cell
surface. M3 induction is inhibited by brefeldin A, which
blocks cis-Golgi apparatus transport, indicating that the in-
tracellular pool may be located in the ER or early Golgi
compartment. Inhibitors of endocytosis (phenylarsine oxide
and cytochalasin B) also affect M3 expression, presumably
due to a requirement for antigen to be endocytosed and
eventually reach the cytoplasm for transport to the ER.
Chloroquine, an inhibitor of the class II exogenous antigen
presentation pathway, had little effect on the expression
level of M3, which may reflect the lack of a lysosomal pro-
cessing requirement for short peptides.
Because MTF presentation to CTLs has been shown to
be TAP dependent (46), TAP deficiency may also affect
M3 induction by exogenous peptide. We analyzed the in-
duction of M3 on splenocytes from TAP-deficient animals
(47) and found that maximum levels of expression could
not be reached even after lengthy incubation times (Fig. 8).
The decrease in efficiency of induction ranged from 50%
reduction for LemA to 80% reduction for ND1. This sug-
gests that there is a requirement for TAP translocation of
exogenously added N-formylated peptides into the ER.
Alternatively, TAP or a TAP-dependent complex may me-
diate peptide association with M3 before maturation and
trafficking to the cell surface can be completed.
Stability of the M3–Peptide Complex. The kinetics of in-
creased M3 surface expression were rapid, with increases
detected at 30 min and levels approaching plateau at 4 h
(Fig. 9 A). Culturing the cells in the presence of peptide for
a longer period of time, i.e., 20 h, further increased M3 ex-
pression. This increase could be due to stabilization of
newly synthesized M3, which could have an additive effect
if M3–peptide complexes on the cell surface are long lived.
To detect relative stability of M3–peptide complexes, we
followed the loss of surface expression on splenocytes after
peptide had been removed from the medium by thorough
washing. At the 2 h time point, no significant change in
fluorescence intensity could be detected for most of the
peptides tested. The fluorescence intensity decreased signif-
Figure 5. N-formylated peptides increase surface expression of M3. (A) C57BL/6 splenocytes were incubated with synthetic listerial peptides (LemA-
fMIGWII; Fr38-fMIVIL), mitochondrial peptides (ND1-fMFFINIL; ND2-fMNPITLA; ND3-fMNLYTVI; ND4-fMLKIILP; ND4L-fMPSTFFN;
ND5-fMINIFTTS; ND6-fMNNYIFV; COI-fMFINRW; COII-fMAYPFQL; COIII-fMTHQTHA; ATPase6-fMNENLFA; ATPase8-fMPQLDTS;
Cytb-fMTNMRKT; and ND1-Unf-MFFINILTL) and chemotactic peptide (fMFLL) at a concentration of 10 mM overnight. Bars represent mean fluo-
rescence intensity after staining with mAb 130 as described. Unf-ND1 shares the same sequence as ND1 but is not formylated. (B) Splenocytes were in-
cubated overnight with varying concentrations of M3-binding peptides. The range of concentrations and the corresponding hatchmarks are shown.
DMSO and Un represent background M3 expression on splenocytes either treated with solvent alone or untreated.429 Chiu et al.
icantly after 4 h for all peptides tested, with 50% reduction
seen between 4 and 6 h after washing. After 12 h, increased
levels of M3 still remained on the cell surface (Fig. 9 B).
Detection of an Intracellular Pool of M3 Molecules. To fur-
ther study the intracellular trafficking of M3 in response to
increased peptide supply, we performed pulse–chase analy-
sis on P388 cells incubated with and without peptide.
[35S]methionine and cysteine were incorporated during a
brief metabolic labeling (20 min) and then chased with or
without the addition of peptide for various periods of time
(Fig. 10). The lysates were immunoprecipitated with mAb
130 or a control antibody (34-2-12S) for H-2Dd. Immuno-
precipitates were digested with EndoH to measure the
transport of class I molecules from the ER (EndoH sensi-
tive) through the mid-Golgi compartment (EndoH resis-
tant). At the zero time point, all molecules are EndoH sen-
sitive, and there is a lack of b2m stably associated with M3
(data not shown). After 1-h chase in the presence of pep-
tide, a significant portion of M3 acquires EndoH resistance
and is associated with b2m. However, when no peptide is
added, M3 remains in an immature state for at least 6 h and
does not appreciably mature to a slower migrating, En-
doH-resistant, b2m-associated form. This result suggests
Figure 6. Cell surface expression of M3 cannot be rescued by lowered
temperature. (A) C57BL/6 splenocytes were incubated overnight at the
indicated temperatures and stained for FACS™ analysis. Surface staining
with mAb 130 is shown (black line) superimposed on background stain-
ing of cells with control antibody (dotted line). Left, 378C; right, 278C.
(B) B6 splenocytes were incubated overnight with 10 mM of various pep-
tides. Bars represent staining with mAb 130 for treatment at either 278C
(gray bars) or 378C (black bars).
Figure 7. Effect of inhibitors on the peptide-induced expression of M3.
C57BL/6 splenocytes preincubated with or without the inhibitor were
cultured overnight with 10 mM peptide and stained for M3 expression.
BFA, 5 mg/ml brefeldin A; CQ, 20 mM chloroquine; CHX, 20 mg/ml
cycloheximide; CB, 10 mM cytochalasin B; PO, 10 mM phenylarsine ox-
ide. The bar labeled b2m shows M3 expression after overnight incuba-
tion with 10 mg/ml human b2m in the absence of peptide.
Figure 8. The loading of M3 with exogenously added peptide is largely
TAP dependent. Splenocytes from TAP-deficient mice in 1293B6 back-
ground (white bars) or from C57BL/6 mice (black bars) were incubated
with 10 mM peptide overnight at 378C. Fluorescence intensity after stain-
ing with mAb 130 is shown for the peptides indicated; treatment with
DMSO (Un) or with a nonformylated version of the ND1 peptide
(ND1-Unf) are also shown.430 H2-M3 Trafficking Is Affected by Antigen Supply
that there is a steady-state intracellular pool of M3 and that
free M3 heavy chain cannot egress from the ER/cis-Golgi
compartment in the absence of antigen. At the 20 h time
point, most of the M3 molecules were degraded in the ab-
sence of peptide, whereas a significant amount of mature
M3 molecules remained in the peptide-treated cells, con-
firming the longevity of M3–peptide complexes detected
by FACS™ analysis. The precipitation of comparable
amounts of immature and mature forms of M3 over time
shows that M3 is truly transported to the cell surface in re-
sponse to peptide and that mAb 130 does not recognize a
peptide-dependent conformation of M3. No difference in
the maturation and stability of H-2Dd can be detected from
peptide-treated and untreated cells. Furthermore, the ki-
netics of M3 trafficking are similar to those of H-2Dd ex-
cept that the M3–peptide complex appears to be more sta-
ble than Dd.
Discussion
We have produced a mAb against the class Ib molecule
H2-M3 that allows us to study the expression and intracel-
lular trafficking of M3. M3 is expressed at low levels on the
surfaces of B cells and can be induced by peptide on the
surface of many cell types, most efficiently on APCs, i.e., B
cells, macrophages, and dendritic cells. Despite high levels
of M3 RNA in the transfected fibroblast line (TR8.4a), M3
expression is not induced on the cell surface. This suggests
that RNA levels are not ultimately the limiting factor in
M3 surface expression and that use of increased ligand sup-
ply requires mechanisms specialized to APCs. We have
demonstrated the existence of an intracellular pool of M3
in APCs that is rapidly transported to the cell surface when
supplied with sufficient antigen. Due to a limited supply of
endogenous peptides, M3 behaves in the wild-type back-
ground as a class Ia molecule does in a TAP-deficient cell.
Under normal conditions, the majority of M3 is retained
and degraded in the ER due to the lack of suitable anti-
gens. Addition of exogenous peptides, or presumably infec-
tion by intracellular bacteria, allows M3 to rapidly mature
with kinetics similar to those for class Ia molecules.
The antigen supply pathway for exogenously added pep-
tide appears to be through endocytosis and then release to
cytoplasm, followed by TAP transport into the ER. Al-
though direct transport of pinocytosed peptide to the ER has
been demonstrated for fluorescently labeled peptides (48), in
the TAP-deficient background, M3 does not reach maxi-
mum cell surface levels. In an analogous experiment where
RMA and RMA-S cells were pulsed with the Kb-binding
peptide SIINFEKL, an antibody specific for Kb–SIINFEKL
detected similar amounts of this complex on the surface of
both cell types (49). In contrast, M3-binding peptides seem
to require peptide translocation from the cytosol into the
Figure 9. Time course study of
peptide-induced M3 surface expres-
sion. (A) The peptides LemA and
COI were added at 10 mM to spleno-
cytes. At each time point, samples
were washed at 48C and stained for
M3 expression. (B) Splenocytes were
incubated with 10 mM of each pep-
tide for 4 h. The cells were washed
three times and cultured without pep-
tide over the course of 12 h. At each
time point, surface expression was as-
sessed by staining with mAb 130.
Figure 10. Pulse–chase analysis of 35S metabolically labeled M3. P388
cells were pulsed with 35S Translabel for 20 min and then harvested or
chased up to 20 h either in the presence or absence of 10 mM LemA pep-
tide. At the time points indicated, cells were lysed and subjected to im-
munoprecipitation with mAb 130 (for M3) and mAb 34-2-12S (for Dd).
Immune complexes were digested with (1) or without (2) EndoH and
separated by SDS-PAGE.431 Chiu et al.
ER. Alternatively, M3 peptide loading may be more
strongly dependent on the chaperone-like function of the
complex of tapasin, Erp57 (50–52), and calreticulin that is
stabilized by TAP. It is unlikely that significant antigen
loading takes place on empty molecules on the cell surface
or through recycling of empty M3, given the inhibitory ef-
fect of phenylarsine oxide and brefeldin A and the com-
plete lack of maturation of the M3 heavy chain during the
pulse–chase in the absence of peptide. It is unclear why M3
surface expression is induced to greater levels on APCs.
This differential expression may be due to differences in the
chaperone environment in APCs or to differences in the
endosome to cytosol pathway in APCs.
Unlike class Ia molecules, the surface expression of M3
cannot be induced by incubation at low temperature (278C),
suggesting that empty M3 is not efficiently transported to the
cell surface. Two possible explanations may account for the
lack of empty M3 on the cell surface. First, M3 may have
lower affinity for b2m, and thus the M3/b2m heterodimer
is less stable than empty class Ia heterodimers. Alternatively,
M3 may be actively retained by an ER chaperone protein
until acquiring a conformation that depends on peptide asso-
ciation. Active retention of empty class I molecules by tapa-
sin has been demonstrated in insect cells (53). To determine
the stability of M3 in vitro, we examined the dissociation of
M3 heavy chain from b2m at a range of temperatures using
a soluble “empty” M3–b2m complex produced in Dro-
sophila cells. We found that the M3–b2m complex is more
stable than that reported for H-2Kb and Db (54; Chun, T.
and C.-R. Wang, unpublished results). Unlike Kb and Db,
empty recombinant M3 molecules are stable at 378C. There-
fore, there may be selective pressure to retain empty M3
molecules intracellularly to prevent the expression of a pool
of N-formylated peptide receptors at the cell surface. In con-
trast to our results, a prior study using an M3/Ld chimera has
shown that M3/Ld can traffic to the cell surface at 278C (55).
The chimera was stabilized by addition of peptides at low
temperature but not at 378C, thus differing substantially from
the behavior of the endogenous M3 molecule. M3 has a
very short cytoplasmic tail (GER) that does not support a
specific ER retention mechanism. Because the M3/Ld chi-
mera contained the a3 domain and transmembrane region
from Ld but was not retained like native M3, it is likely that
the a3 domain and/or the transmembrane region of M3
may play an important role in M3 trafficking by mediating
differential interaction with ER chaperone(s).
A given class Ia molecule may present 100–1,000 differ-
ent peptide sequences on the surface of a cell (56); however,
these peptides must share an allele-specific motif for that class
I molecule. The range of peptides that bind M3 appears to
be limited by N-formylation and hydrophobicity rather
than specific sequence constraints. The endogenous supply
of N-formylated peptide is limited by the amount gleaned
from mitochondrial protein synthesis or supplied on degra-
dation of mitochondria. The limited supply of mitochon-
drial peptide is compounded by the infrequent occurrence
of sequences that bind M3, that is, only 2/13 possible pep-
tides. It appears that M3 complexes with peptide are more
stable than most class Ia–peptide complexes (57). This can
counteract the extreme lack of peptide in maintaining some
surface expression of the M3, which may be critical for the
generation of T cell repertoire and/or maintenance of self-
tolerance to M3.
The expression pattern of M3 has implications for its
role in antigen presentation. In the uninfected condition,
the basal surface level of M3 is minimal. Upon invasion by
an intracellular pathogen such as L. monocytogenes, empty M3
is available for immediate transport to the cell surface in
proportion to antigen supply, with little competition from
endogenous peptides. It is possible that there may be as
many or more M3–antigen complexes on the cell surface as
there are class Ia molecules complexed with a specific pep-
tide. Although the overall level of M3 is z20–100 times
less than that of a class Ia molecule, the proportion of M3
molecules containing a particular antigenic peptide may be
100–1,000 times greater due to the lack of competition
from self-peptides. In further experiments, the immature
form of M3 could be induced to mature by addition of
peptide at the 6 h time point of the chase (data not shown),
demonstrating that the immature molecules are peptide re-
ceptive and reside in a compartment where peptide can be
loaded. This allows M3 to be a potent antigen presentation
moiety despite its low expression level. In support of this
concept, M3-restricted T cells have been generated in vitro
by stimulation with peptide-coated splenocytes (58), and
we have successfully initiated M3-restricted T cell lines by
immunization of mice with N-formyl peptide–coated
APCs (Chun, T. and C.-R. Wang, unpublished results).
A significant aspect of our system is that the antigen-
dependent behavior of M3 can be analyzed in the presence
of intact antigen processing systems. High-affinity ligands
for M3 can be easily screened by induction of surface ex-
pression; however, this induction can only be found on ap-
propriate APCs. Had we relied on the frequently used
RMA-S system, no induction of M3 would have been de-
tected. As unconventional antigens and nonclassical mole-
cules are increasingly found to play a role in specific immu-
nity, it will become important not to assume that all cell
types will give equal information about antigen presenta-
tion. The recent demonstration of the importance of exog-
enous antigen presentation by bone marrow–derived APCs
in initiating the CTL response suggests that it is important
to look for antigens accessible to MHC molecules in the
most relevant cell type (59).
Due to the efficient presentation of exogenous peptide
by M3 and its lack of polymorphism, an M3-based peptide
vaccine may be a useful method for boosting specific
immunity to intracellular pathogens in a broad range of re-
cipients. Southern blot analysis has revealed no genetic hu-
man homologue of M3 (4); however, lack of sequence ho-
mology does not preclude functional equivalence as seen in
the case of the class Ib molecules Qa-1 and HLA-E, which
bind leader peptides from class Ia molecules in mice and
humans, respectively (60–62). The unusual cell biology of
M3 described here may provide the basis for the search for
functional homologues of M3 in humans.432 H2-M3 Trafficking Is Affected by Antigen Supply
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